
Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Nanatinostat,Valganciclovir Hydrochloride
Therapeutic Area : Oncology
Study Phase : Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Viracta Therapeutics Announces NAVAL-1 Trial Closure and Strategic Alternatives
Details : Viracta's lead program, Nana-Val evaluates the all-oral combination of nanatinostat & valganciclovir in a Phase 2 clinical trial for the treatment of EBV-positive relapsed/refractory (R/R) lymphoma.
Product Name : Nana-Val
Product Type : Miscellaneous
Upfront Cash : Inapplicable
December 26, 2024
Lead Product(s) : Nanatinostat,Valganciclovir Hydrochloride
Therapeutic Area : Oncology
Highest Development Status : Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Nanatinostat,Valganciclovir Hydrochloride
Therapeutic Area : Oncology
Study Phase : Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Viracta Announces Positive Data from NAVAL-1 Trial and Updated Nana-val Development Plan
Details : Viracta's lead program, Nana-Val evaluates the all-oral combination of nanatinostat & valganciclovir in a Phase 2 clinical trial for the treatment of EBV-positive relapsed/refractory (R/R) lymphoma.
Product Name : Nana-val
Product Type : Miscellaneous
Upfront Cash : Inapplicable
August 14, 2024
Lead Product(s) : Nanatinostat,Valganciclovir Hydrochloride
Therapeutic Area : Oncology
Highest Development Status : Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Tovorafenib
Therapeutic Area : Oncology
Study Phase : Approved FDF
Recipient : XOMA
Deal Size : $108.0 million
Deal Type : Agreement
XOMA Receives $8.1 Million Milestone for Day One Biopharmaceuticals’ Priority Voucher
Details : XOMA acquired potential milestones associated with Ojemda (tovorafenib), approved for patients 6 months age and older with relapsed or refractory pediatric low-grade glioma with BRAF V600 mutation.
Product Name : Ojemda
Product Type : Miscellaneous
Upfront Cash : Undisclosed
June 12, 2024
Lead Product(s) : Tovorafenib
Therapeutic Area : Oncology
Highest Development Status : Approved FDF
Recipient : XOMA
Deal Size : $108.0 million
Deal Type : Agreement

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Nanatinostat,Valganciclovir Hydrochloride
Therapeutic Area : Oncology
Study Phase : Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Viracta Reports Positive Results in NAVAL-1 Trial for EBV+ Lymphoma
Details : Viracta’s lead program VRx-3996 combines nanatinostat and valganciclovir in a Phase 2 trial for EBV-positive relapsed/refractory lymphoma, aiming to address unmet patient needs.
Product Name : Nana-val
Product Type : Miscellaneous
Upfront Cash : Inapplicable
April 15, 2024
Lead Product(s) : Nanatinostat,Valganciclovir Hydrochloride
Therapeutic Area : Oncology
Highest Development Status : Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable

Details : 14-C Nanatinostat is a Radiolabeled Compounds drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Neoplasms.
Product Name : Undisclosed
Product Type : Radiolabeled Compound
Upfront Cash : Inapplicable
March 08, 2024

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Nanatinostat,Valganciclovir Hydrochloride
Therapeutic Area : Oncology
Study Phase : Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Viracta Completes Enrollment in NAVAL-1 Trial for Peripheral T-Cell Lymphoma
Details : Nana-val (nanatinostat with valganciclovir) is an all-oral investigational therapy targeting Epstein-Barr virus (EBV)-associated cancers. It is being evaluated for EBV+ peripheral T-cell lymphoma.
Product Name : Nana-val
Product Type : Miscellaneous
Upfront Cash : Inapplicable
February 29, 2024
Lead Product(s) : Nanatinostat,Valganciclovir Hydrochloride
Therapeutic Area : Oncology
Highest Development Status : Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Nanatinostat,Valganciclovir Hydrochloride
Therapeutic Area : Oncology
Study Phase : Phase I/ Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Nana-val (nanatinostat in combination with valganciclovir), a first-in-class, all-oral investigational therapy targeting Epstein-Barr virus (EBV)-associated cancers. It is being evaluated for the treatment of EBV-related nasopharyngeal carcinoma.
Product Name : Nana-val
Product Type : Miscellaneous
Upfront Cash : Inapplicable
December 12, 2023
Lead Product(s) : Nanatinostat,Valganciclovir Hydrochloride
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Nanatinostat,Valganciclovir Hydrochloride
Therapeutic Area : Oncology
Study Phase : Phase I/ Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Nana-val (nanatinostat + valganciclovir) is a combination medicine. Nanatinostat is an orally available histone deacetylase (HDAC) inhibitor. It is being evaluated in phase 1/2 clinical trials for the treatment of Epstein-Barr Virus-positive solid tumors...
Product Name : Nana-val
Product Type : Miscellaneous
Upfront Cash : Inapplicable
December 04, 2023
Lead Product(s) : Nanatinostat,Valganciclovir Hydrochloride
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Nanatinostat,Valganciclovir Hydrochloride
Therapeutic Area : Oncology
Study Phase : Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Nana-val (nanatinostat) is an oral histone deacetylase inhibitor, selective for specific Class I HDACs isoform. It is currently being investigated in combination with valganciclovir for R/R EBV+ PTCL.
Product Name : Nana-val
Product Type : Miscellaneous
Upfront Cash : Inapplicable
June 28, 2023
Lead Product(s) : Nanatinostat,Valganciclovir Hydrochloride
Therapeutic Area : Oncology
Highest Development Status : Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Nanatinostat,Valganciclovir Hydrochloride
Therapeutic Area : Oncology
Study Phase : Preclinical
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Nana-val (nanatinostat and valganciclovir) is an orally available histone deacetylase inhibitor. It is selective for specific isoforms of Class I HDACs, which are key to inducing viral genes that are epigenetically silenced in EBV-associated malignancies...
Product Name : Nana-val
Product Type : Miscellaneous
Upfront Cash : Inapplicable
January 19, 2023
Lead Product(s) : Nanatinostat,Valganciclovir Hydrochloride
Therapeutic Area : Oncology
Highest Development Status : Preclinical
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
